Nightfood Holdings Subsidiary TechForce Deploys Autonomous Lab Robot in Pharmaceutical Automation Milestone

June 1st, 2026 1:45 PM
By: Newsworthy Staff

Nightfood Holdings subsidiary TechForce Robotics successfully deployed its first autonomous laboratory robot, LIM-E, under a joint development agreement with Oncotelic Therapeutics, marking the company's expansion into pharmaceutical and life sciences automation.

Nightfood Holdings Subsidiary TechForce Deploys Autonomous Lab Robot in Pharmaceutical Automation Milestone

Nightfood Holdings Inc. (OTCQB: NGTF) announced that its subsidiary, TechForce Robotics, has successfully completed Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the initial deployment of LIM-E, an autonomous laboratory support robot. The deployment marks TechForce's first expansion into pharmaceutical and laboratory automation and validates the adaptability of its AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments.

TechForce said the deployment completed the initial operational goals established under the companies' April 2026 collaboration agreement and will provide operational data and workflow insights to support future automation initiatives. The companies plan to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows and other automation applications, while Nightfood views healthcare, life sciences and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service platform.

This milestone is significant because it demonstrates the versatility of TechForce's AI-enhanced robotics platform and its potential to address labor shortages and efficiency challenges in pharmaceutical laboratories. By automating routine tasks, LIM-E can free up skilled laboratory personnel for higher-value activities, potentially accelerating research and development timelines. The deployment also positions Nightfood to capture a share of the growing laboratory automation market, which is driven by increasing demand for precision, reproducibility, and throughput in drug development and manufacturing.

For more information about Nightfood Holdings, visit www.nightfoodholdings.com. For more information about Oncotelic Therapeutics, visit www.oncotelic.com. To view the full press release, visit https://ibn.fm/RFkfL.

Source Statement

This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,

blockchain registration record for the source press release.
;